Zach Adash's questions to BioLife Solutions Inc (BLFS) leadership • Q2 2025
Question
An analyst from Stephens Inc. asked for management's outlook on the EVO and THAW business segments and how they fit into the company's long-term portfolio, particularly given the focus on cell processing. He also inquired about demand trends in the early-stage clinical portion of the media business amid ongoing funding challenges.
Answer
Chairman & CEO Roderick de Greef stated that the EVO product line is still under evaluation for its long-term strategic fit, while the Thaw product line is considered a definite part of the portfolio due to its consistent revenue generation. Regarding early-stage clinical demand, de Greef acknowledged that while all customer segments grew year-over-year, the 'other clinical customers' (smaller, earlier-stage) showed the lightest growth, indicating some softness, but still positive year-over-year performance.